Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Augusto Vaglio
ResearcherPublications, citations & collaboration network
Augusto Vaglio is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 15 works, 50 citations, an h-index of 4 and an i10-index of 1.
15
Works
50
Citations
4
h-index
1
i10-index
IDs:OpenAlex
How has Augusto Vaglio's publication output changed over time?
ScholarIQpublication output · 2024–2025
Output grew300% over the shown period — from 2 works in 2024 to 8 in 2025.
2
8
20242025
What are the most-cited papers on Augusto Vaglio?
ScholarIQmost cited works
Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis)
Francesco Pegoraro, Matthias Papo, Fleur Cohen‐Aubart, Francesco Peyronel, Gianmarco Lugli, Irene Trambusti, G. Baulier, Mathilde de Menthon, Tanguy Le Scornet, E. Oziol, Nicole Ferreira-Maldent, Olivier Hermine, Benoit Faucher, Dirk Koschel, Nicole Straetmans, Noémie Abisror, Benjamin Terrier, François Lifermann, Jérôme Razanamahery, Yves Allenbach, Jeremy Keraen, Sophie Bulifon, B. Hervier, Annamaria Buccoliero, Frédéric Charlotte, Quentin Monzani, Samia Boussouar, Natalia Shor, Annalisa Tondo, Stéphane Barète, Ahmed Idbaïh, Abdellatif Tazi, Elena Sieni, Zahir Amoura, Jean‐François Emile, Augusto Vaglio, Julien Haroche
EClinicalMedicine. 202422 CitationsOPEN ACCESS
Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study
Francesco Pegoraro, Francesco Catamerò, Federica Allegretta, Giulia Palazzini, Francesco Peyronel, Eli L. Diamond, Augusto Vaglio
Blood Advances. 20259 CitationsOPEN ACCESS
MEK inhibitors are effective in Erdheim–Chester disease regardless of MAPK pathway mutations
Francesco Pegoraro, Fleur Cohen-Aubart, Matthias Papo, Francesco Catamerò, Jérôme Razanamahery, Zahir Amoura, Jean‐François Emile, Augusto Vaglio, Julien Haroche
S149476849. 20255 CitationsOPEN ACCESS
New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis
Giovanni Maria Rossi, Augusto Vaglio
Journal of Clinical Medicine. 20254 CitationsOPEN ACCESS
Anakinra improves retention rate of targeted treatments in Erdheim–Chester disease
Corrado Campochiaro, Alessandro Tomelleri, Francesco Catamerò, Francesco Pegoraro, Augusto Vaglio, Lorenzo Dagna
Lara D. Veeken. 20253 Citations
Related on ScholarIQ
Sorbonne Université
Institution
Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis)
Paper
Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study
Paper
MEK inhibitors are effective in Erdheim–Chester disease regardless of MAPK pathway mutations
Paper
New Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis
Paper
Anakinra improves retention rate of targeted treatments in Erdheim–Chester disease
Paper